Savara Inc Stock Investor Sentiment

SVRA Stock  USD 3.36  0.11  3.17%   
About 62% of Savara's investor base is looking to short. The analysis of the overall investor sentiment regarding Savara Inc suggests that many traders are alarmed. The current market sentiment, together with Savara's historical and current headlines, can help investors time the market. In addition, many technical investors use Savara Inc stock news signals to limit their universe of possible portfolio assets.
  

Savara Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Savara can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at thelincolnianonline.com         
Vestal Point Capital LP Raises Holdings in Savara Inc
news
2 days ago at thelincolnianonline.com         
Acquisition by Elam Nevan C of 10841 shares of Savara at 0.82 subject to Rule 16b-3
news
few days ago at www.macroaxis.com         
Acquisition by Ramsay David A of 100000 shares of Savara at 2.876 subject to Rule 16b-3
Macroaxis News
few days ago at finance.yahoo.com         
Estimating The Fair Value Of Savara Inc.
Yahoo News
over a week ago at businesswire.com         
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inha...
businesswire News
over a week ago at businesswire.com         
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inha...
businesswire News
over a week ago at businesswire.com         
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inha...
businesswire News
over a week ago at businesswire.com         
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inha...
businesswire News
over a week ago at finance.yahoo.com         
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inha...
Yahoo News
over a week ago at simplywall.st         
Independent Director of Savara Picks Up 4.5 percent More Stock
Simply Wall St News at Macroaxis
over a week ago at investing.com         
Savara director Joseph McCracken acquires 59,071 in common stock
Investing News at Macroaxis
over a week ago at gurufocus.com         
Insider Buying Alert Joseph Mccracken Acquires 20,000 Shares of Savara Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Director David Ramsay Acquires 100,000 Shares of Savara Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Acquisition by Mccracken Joseph S of 20000 shares of Savara at 2.9536 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Acquisition by Ramsay David A of 100000 shares of Savara at 2.876 subject to Rule 16b-3
Investing News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Savara that are available to investors today. That information is available publicly through Savara media outlets and privately through word of mouth or via Savara internal channels. However, regardless of the origin, that massive amount of Savara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Savara news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Savara relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Savara's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Savara alpha.

Savara Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Mathers Edward T of 333333 shares of Savara at 3.0 subject to Rule 16b-3
09/13/2024
2
Acquisition by Pratt Raymond Dennis of 3500 shares of Savara at 1.5434 subject to Rule 16b-3
09/20/2024
3
Savara Announces Expanded Access Program for Molgramostim Inhalation Solution for Patients with Autoimmune Pulmonary Alveolar Proteinosis
09/27/2024
4
Acquisition by Elam Nevan C of 1758 shares of Savara at 0.82 subject to Rule 16b-3
10/17/2024
5
Disposition of 381 shares by Anne Erickson of Savara at 3.57 subject to Rule 16b-3
10/21/2024
6
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis , is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV
10/22/2024
7
Disposition of 49950 shares by Pratt Raymond Dennis of Savara at 3.97 subject to Rule 16b-3
11/08/2024
8
Jennison Associates LLCs Strategic Acquisition of Savara Inc Shares
11/13/2024
9
Acquisition by Ramsay David A of 100000 shares of Savara at 2.876 subject to Rule 16b-3
11/18/2024
10
Director David Ramsay Acquires 100,000 Shares of Savara Inc
11/19/2024
11
Independent Director of Savara Picks Up 4.5 percent More Stock
11/21/2024
12
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution in Patients with Autoimmune Pulmonary Alveol...
11/22/2024
13
Estimating The Fair Value Of Savara Inc.
11/25/2024
14
Vestal Point Capital LP Raises Holdings in Savara Inc
11/29/2024

Complementary Tools for Savara Stock analysis

When running Savara's price analysis, check to measure Savara's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Savara is operating at the current time. Most of Savara's value examination focuses on studying past and present price action to predict the probability of Savara's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Savara's price. Additionally, you may evaluate how the addition of Savara to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated